AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT01319240
Drug: liraglutide
RxNorm normalized name: Liraglutide
DrugBank: Liraglutide (DB06655)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Subjects will be randomised to one out of six possible treatment sequences. Single dose, administered subcutaneously (under the skin) on three separate dosing visits.
Trial: NCT03906721
Drug: Oxycodone
RxNorm normalized name: Oxycodone
DrugBank: Oxycodone (DB00497)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: An opioid used for analgesia.
Trial: NCT03227016
Drug: veliparib
RxNorm normalized name: veliparib
DrugBank: Veliparib (DB07232)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topotecan at increasing doses (1x or 2x per day) will be administered in each cycle.
Trial: NCT03227016
Drug: Topotecan
RxNorm normalized name: Topotecan
DrugBank: Topotecan (DB01030)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Topotecan at dose 1.25 mg/m2 will be administered in each cycle.
Trial: NCT03724266
Drug: Chitosan
RxNorm normalized name: Chitosan
DrugBank: Chitosan low molecular weight (20-200 mpa.s) (DB14155)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: chitosan will be used as intracanal medication
Trial: NCT01398189
Drug: clozapine
RxNorm normalized name: Clozapine
DrugBank: Clozapine (DB00363)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: C-11 clozapine
Trial: NCT03844594
Drug: Eptifibatide Injection
RxNorm normalized name: eptifibatide Injection
DrugBank: Eptifibatide (DB00063)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Recommendation: first, intravenously or intraductal injection of 135ug / kg (completed in 5 minutes), followed by continuous intravenous infusion of 0.75ug / kg / min for 24 hours.
Trial: NCT00073892
Drug: PI-88
RxNorm normalized name: Heparanase inhibitor PI-88
DrugBank: Muparfostat (DB05808)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 250 mg/day injected subcutaneously on four consecutive days each week in a 4- week cycle
Trial: NCT03233204
Drug: Olaparib
RxNorm normalized name: Olaparib
DrugBank: Olaparib (DB09074)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Given PO
Trial: NCT01879423
Drug: Lamotrigine Dispersible/Chewable tablets 5mg*5
DrugBank: Lamotrigine (DB00555)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Single dose of lamotrigine dispersible/chewable 5mg\*5 tablets at Day1 and Single dose of Lamotrigine Compressed 25mg\*1 tablet at Day15
Trial: NCT01879423
Drug: Lamotrigine Compressed tablet 25mg
RxNorm normalized name: lamotrigine Oral Tablet
DrugBank: Lamotrigine (DB00555)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Single dose of lamotrigine compressed 25mg\*1 tablet at Day1 and Single dose of lamotrigine dispersible/chewable 5mg\*5 tablets at Day15
Trial: NCT00861614
Drug: Ipilimumab
RxNorm normalized name: Ipilimumab
DrugBank: Ipilimumab (DB06186)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 5 mg/ml solution, Intravenous, 10 mg/kg, Every 3 weeks for up to 4 doses in the Induction Phase. Every 12 weeks in the Maintenance Phase, Up to 24 weeks in Induction, 48+ weeks in the Maintenance Phase, or until Treatment Stopping Criteria are met, withdrawal of consent, lost to follow-up, death, study closure
Trial: NCT03451110
Drug: lemborexant
RxNorm normalized name: Lemborexant
DrugBank: Lemborexant (DB11951)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: oral tablet
Trial: NCT03451110
Drug: Loestrin
RxNorm normalized name: Lo Loestrin Fe
DrugBank: Norethisterone (DB00717)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: oral tablet
Trial: NCT03451110
Drug: famotidine
RxNorm normalized name: Famotidine
DrugBank: Famotidine (DB00927)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: oral tablet
Trial: NCT03451110
Drug: fluconazole
RxNorm normalized name: Fluconazole
DrugBank: Fluconazole (DB00196)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: oral tablet
Trial: NCT00847795
Drug: Avotermin
RxNorm normalized name: avotermin
DrugBank: Avotermin (DB11955)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intradermal administration
Trial: NCT02452684
Drug: Eszopiclone
RxNorm normalized name: Eszopiclone
DrugBank: Eszopiclone (DB00402)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The usual dosage of eszopiclone is 2 mg per dose for adults and 1 mg per dose for elderly participants, taken orally before bedtime. The dosage may be adjusted according to the participant's symptoms, but a single dose should not exceed 3 mg in adults and 2 mg in elderly participants.
Trial: NCT01837329
Drug: Tetrathiomolybdate
RxNorm normalized name: Tetrathiomolybdate
DrugBank: Tetrathiomolybdate (DB05088)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dose Escalation - Dose level -1: 20 mg TM orally 3 x daily x 21 days in combination with carboplatin IV area under the curve (AUC) = 6 and pemetrexed IV 500/mgm2 day 1 x 1 cycle.~Dose level 1: 40 mg TM orally 3 x daily x 21 days in combination with carboplatin IV AUC = 6 and pemetrexed IV 500 mg/m2 day 1 x 1 cycle.~Dose level 2: 60 mg TM orally 3 x daily x 21 days in combination with carboplatin IV AUC = 6 and pemetrexed IV 500 mg/m2 day 1 x 1 cycle.~Patients in the dose-expansion cohort will continue on carboplatin and pemetrexed (without TM) at the discretion of the treating physician.~Dose Expansion - Maximum tolerated dose of TM determined from the dose-escalation cohorts combined with carboplatin IV AUC = 6 and pemetrexed IV 500 mg/m2 day 1 x 4 cycles.
Trial: NCT03554993
Drug: CC-99677
RxNorm normalized name: CC
DrugBank: Cholecalciferol (DB00169)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CC-99677
Trial: NCT01404208
Drug: D-Cycloserine
RxNorm normalized name: D-Cycloserine
DrugBank: Cycloserine (DB00260)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 25mg dose for children weighing between 22.5kg and 45kg (dose = approx. .7mg/kg) 50mg dose for children weighing greater than 46kg (dose = approx. .7mg/kg) Dose given 7 times, every seven days, except for the third dose, which will be given three days after the second dose. All doses given 1 hour prior to therapy session.
Trial: NCT00634595
Drug: E10A
RxNorm normalized name: Empagliflozin
DrugBank: Empagliflozin (DB09038)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: E10A 1\*10(12)VP, intratumoral injection, d1 d8, repeat every 3 weeks for 4 cycles
Trial: NCT00634595
Drug: Cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 25 mg/m2/d ivd d3 d4 d5, repeat every 3 weeks for 4 cycles.
Trial: NCT00634595
Drug: Paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 160 mg/m2 ivd d3, repeat every 3 weeks for 4 cycles.
Trial: NCT02456038
Drug: Asfotase Alfa (ALXN1215)
DrugBank: Asfotase alfa (DB09105)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT00412217
Drug: Erlotinib
RxNorm normalized name: Erlotinib
DrugBank: Erlotinib (DB00530)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Erlotinib will be given as 150 mg PO once daily.
Trial: NCT04794413
Drug: Pimavanserin
RxNorm normalized name: Pimavanserin
DrugBank: Pimavanserin (DB05316)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pimavanserin is a serotonin receptor inverse agonist used in treatment of psychosis in Parkinson's disease.
Trial: NCT00297713
Drug: ALTU-238
RxNorm normalized name: Altuviiio
DrugBank: Efanesoctocog alfa (DB16662)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00239213
Drug: catechin extracts (health food)
RxNorm normalized name: catechin
DrugBank: Cianidanol (DB14086)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01500213
Drug: Rolapitant
RxNorm normalized name: Rolapitant
DrugBank: Rolapitant (DB09291)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 200 mg PO
Trial: NCT01500213
Drug: Granisetron
RxNorm normalized name: Granisetron
DrugBank: Granisetron (DB00889)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 10 mcg/kg IV
Trial: NCT01500213
Drug: Dexamethasone
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 20 mg PO and 8 mg PO
Trial: NCT00693602
Drug: Erwinase
RxNorm normalized name: Erwinase
DrugBank: Asparaginase Erwinia chrysanthemi (DB08886)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy
Trial: NCT01352585
Drug: Anagrelide hydrochloride
RxNorm normalized name: Anagrelide Hydrochloride
DrugBank: Anagrelide (DB00261)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 0.5 mg hard capsules, dosing decisions will be made by the treating physician
Trial: NCT03496974
Drug: Bermekimab Monoclonal Antibody 200 mg
RxNorm normalized name: Anti-VEGF monoclonal antibody
DrugBank: Bermekimab (DB14947)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg subcutaneous injection
Trial: NCT03496974
Drug: Bermekimab Monoclonal Antibody 400 mg
RxNorm normalized name: Anti-VEGF monoclonal antibody
DrugBank: Bermekimab (DB14947)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 mg subcutaneous injection
Trial: NCT00101127
Drug: docetaxel
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00101127
Drug: gemcitabine hydrochloride
RxNorm normalized name: Gemcitabine Hydrochloride
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT02691195
Drug: Ropivacaine
RxNorm normalized name: Ropivacaine
DrugBank: Ropivacaine (DB00296)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: patients were received an ultrasound-guided serratus plane block, the serratus plane was injected with 0.5% ropivacaine 0.4ml/Kg.
Trial: NCT04551599
Drug: Danicopan
RxNorm normalized name: Danicopan
DrugBank: Danicopan (DB15401)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A single dose of danicopan (200 milligrams) will be administered orally.
Trial: NCT03704584
Drug: Treatment Group: Lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Subjects will receive an injection of lidocaine (1% lidocaine HCl).
Trial: NCT01042509
Drug: Alemtuzumab and rituximab
RxNorm normalized name: Alemtuzumab
DrugBank: Rituximab (DB00073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Alemtuzumab at 10mg subcutaneously daily for 3 doses (days 1, 2 and 3) Rituximab at 100mg intravenously weekly for 4 doses (days 4, 11, 18 and 25
Trial: NCT00027677
Drug: halofuginone hydrobromide
RxNorm normalized name: Halofuginone hydrobromide
DrugBank: Halofuginone (DB04866)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01685853
Drug: Bisacodyl plus PEG-CS
RxNorm normalized name: MyoGesic-CS
DrugBank: Bisacodyl (DB09020)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: * the day before colonoscopy: 3-4 bisacodyl tablets (according to patient bowel habit) at bedtime~* the morning of colonoscopy: PEG-CS (2 litres) starting 5 hours before the exam
Trial: NCT00908076
Drug: LUBIPROSTONE
RxNorm normalized name: Lubiprostone
DrugBank: Lubiprostone (DB01046)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Subjects will be randomized into placebo and study groups. Half of the study group (N=39) will be given lubiprostone (24 mcg) twice daily; the other half will receive matching placebo twice daily.
Trial: NCT02607956
Drug: DTG
RxNorm normalized name: Dolutegravir
DrugBank: Dolutegravir (DB08930)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 50 mg tablets administered orally, once daily
Trial: NCT02607956
Drug: F/TAF
RxNorm normalized name: Emtricitabine/Tenofovir Alafenamide
DrugBank: Emtricitabine (DB00879)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 200/25 mg tablets administered orally, once daily
Trial: NCT01036932
Drug: Granulocyte Colony Stimulating Factor
RxNorm normalized name: Granulocyte colony stimulating factor
DrugBank: Filgrastim (DB00099)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Dose of 5 µg/kg s/c at days 1, 2, 3, 4, 5, and then every 3rd day till day 28 (total 12 doses) along with the standard therapy.
Trial: NCT04048226
Drug: Dexmedetomidine +Ketamine
DrugBank: Dexmedetomidine (DB00633)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: The patients in this group will be connected to the syringe pump that contain mixture of dexmedetomidine and ketamine with starting infusion at a rate of 0.1 ml/kg/hr till the end of the surgery. The solution will contain 2 ug dexmedetomidine/ml and 1 mg ketamine/ml.
Trial: NCT01745835
Drug: 1L Coolprep® and Bisacodyl
DrugBank: Bisacodyl (DB09020)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1. Coolprep® (TaeJoon Pharmaceuticals, Seoul, Korea)~   \* Compositions/1L : Sodium Chloride 2.691g Potassium Chloride 1.015g Anhydrous sodium sulfate 7.5g PEG 3350 100g ascorbic acid 4.7g sodium ascorbate 5.9g~2. Dulcolax-S® (Boehringer Ingelheim ,Seoul, Korea) \* composition /1 tablet : Bisacodyl 5mg, docusate sodium 16.75mg
Trial: NCT00636168
Drug: ipilimumab
RxNorm normalized name: Ipilimumab
DrugBank: Ipilimumab (DB06186)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: IV solution, IV, 10 mg/kg, 4x every 21 days, then starting from Week 24 every 12 weeks until Week 156 (3 years), disease recurrence, unacceptable toxicity or patient withdrawal
Trial: NCT01634295
Drug: S-amlodipine 2.5mg
DrugBank: Amlodipine (DB00381)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: * S-amlodipine 2.5mg QD 4 weeks~* With the others investigation product placebo 4 tabs QD 4 weeks.
Trial: NCT04066296
Drug: Liposomal bupivacaine
RxNorm normalized name: bupivacaine liposome
DrugBank: Bupivacaine (DB00297)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Injection of either liposomal bupivicaine or standard local anesthetic during surgical procedure.
Trial: NCT02172586
Drug: Telmisartan
RxNorm normalized name: Telmisartan
DrugBank: Telmisartan (DB00966)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02172586
Drug: Losartan
RxNorm normalized name: Losartan
DrugBank: Losartan (DB00678)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02172586
Drug: Hydrochlorothiazide
RxNorm normalized name: Hydrochlorothiazide
DrugBank: Hydrochlorothiazide (DB00999)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01634295
Drug: S-amlodipine 5mg
RxNorm normalized name: S-amlodipine
DrugBank: Levamlodipine (DB09237)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: * S-amlodipine 2.5mg QD 6weeks~* With the others investigation product placebo 4 tabs QD 6 weeks.
Trial: NCT01145326
Drug: 4% lidocaine gel application with sham microneedle device
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Topical 4% lidocaine gel (LG4) applied to subject, after application of sham microneedle device (FMA).
Trial: NCT01145326
Drug: Microneedle-facilitated lidocaine application
RxNorm normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Application of 4% lidocaine gel (LG4), after application of microneedle (FMA) device
Trial: NCT03166215
Drug: TAK-935
RxNorm normalized name: TAK-243
DrugBank: TAK-243 (DB15013)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TAK-935 tablets.
Trial: NCT04309578
Drug: Trastuzumab, Capecitabine and Cisplatin
DrugBank: Trastuzumab (DB00072)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: * Trastuzumab intravenous administration at a loading dose of 8 mg/kg on day 1 followed by 6 mg/kg every 3 weeks~* Capecitabine oral administration at a dose of 1000 mg/m2 twice daily for 14 days every 3 weeks (from evening on day 1 to morning on day 15)~* Cisplatin intravenous administration at a dose of 80 mg/m2 on day 1
Trial: NCT00782600
Drug: CR 2
RxNorm normalized name: Paxil CR 25mg Tablet
DrugBank: Paroxetine (DB00715)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 50 mg medium release CR once daily for one day
Trial: NCT00985959
Drug: Melphalan
RxNorm normalized name: Melphalan
DrugBank: Melphalan (DB01042)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Melphalan 9 mg/m2 will be taken orally (by mouth) on Days 1, 2, 3 and 4 of 6-week cycle up to 9 cycles
Trial: NCT00981851
Drug: Tiotropium (Spiriva) + Salbutamol (Ventolin)
RxNorm normalized name: tiotropium Inhalation Powder [Spiriva]
DrugBank: Tiotropium (DB01409)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 time inhalation of 5 mcg of Tiotropium bromide by Respimat and 400 mcg of Salbutamol by Volume Spacer. cigarette smoking
Trial: NCT01590732
Drug: Carboplatin
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT01590732
Drug: Etoposide
RxNorm normalized name: Etoposide
DrugBank: Etoposide (DB00773)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT01590732
Drug: Ifosfamide
RxNorm normalized name: Ifosfamide
DrugBank: Ifosfamide (DB01181)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT01402596
Drug: Midazolam
RxNorm normalized name: Midazolam
DrugBank: Midazolam (DB00683)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 0,4 mg per kg - intranasal midazolam - once
Trial: NCT01402596
Drug: Chloral Hydrate
RxNorm normalized name: Chloral Hydrate
DrugBank: Chloral hydrate (DB01563)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg per kg, rectal
Trial: NCT00433615
Drug: R744
RxNorm normalized name: Remdesivir
DrugBank: Remdesivir (DB14761)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 100μg(s.c./i.v.)/4 week for 8 weeks, then 25\~400μg(s.c./i.v.)/4 week for 40 weeks
Trial: NCT03093064
Drug: Natalizumab
RxNorm normalized name: Natalizumab
DrugBank: Natalizumab (DB00108)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Natalizumab is a humanized monoclonal antibody against the cell adhesion molecule α4-integrin, currently licensed for the treatment of multiple sclerosis and Crohn's disease.
Trial: NCT01590732
Drug: Romidepsin
RxNorm normalized name: Romidepsin
DrugBank: Romidepsin (DB06176)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT00433615
Drug: R744
RxNorm normalized name: Remdesivir
DrugBank: Remdesivir (DB14761)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 150μg(s.c./i.v.)/4 week for 8 weeks, then 25\~400μg(s.c./i.v.)/4 week for 40 weeks
Trial: NCT03374670
Drug: Eylea
RxNorm normalized name: Eylea
DrugBank: Aflibercept (DB08885)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Zimura in combination with Eylea
Trial: NCT00392470
Drug: irinotecan hydrochloride
RxNorm normalized name: Irinotecan Hydrochloride
DrugBank: Irinotecan (DB00762)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00460707
Drug: Casopitant 150 mg
RxNorm normalized name: maropitant 16 MG
DrugBank: Casopitant (DB06634)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Casopitant 150 mg will be available as white, film-coated tablets. Casopitant tablets will be taken with 240 milliliters (mL) of water at room temperature on an empty stomach.
Trial: NCT00460707
Drug: Ketoconazole
RxNorm normalized name: Ketoconazole
DrugBank: Ketoconazole (DB01026)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ketoconazole will be available as 200 mg tablets which will be taken with 240 mL of water on an empty stomach (after a 2 hour fast on Day 4 of Treatment Period 2 and after a 1 hour fast on all other dosing days).
Trial: NCT00460707
Drug: Casopitant 150 mg matching placebo
DrugBank: Casopitant (DB06634)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Casopitant 150 mg matching placebo will be available as white, film-coated tablets.
Trial: NCT00460707
Drug: Casopitant 50 mg
RxNorm normalized name: maropitant 16 MG
DrugBank: Casopitant (DB06634)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Casopitant 50 mg will be available as pale orange, film-coated tablets. Casopitant tablets will be taken with 240 mL of water at room temperature on an empty stomach.
Trial: NCT00460707
Drug: Casopitant 50 mg matching placebo
DrugBank: Casopitant (DB06634)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Casopitant 50 mg matching placebo will be available as pale orange, film-coated tablets.
Trial: NCT04676685
Drug: E2730
RxNorm normalized name: Ethinylestradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: E2730 capsules.
Trial: NCT00002756
Drug: asparaginase
RxNorm normalized name: Asparaginase
DrugBank: Asparaginase Escherichia coli (DB00023)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00002756
Drug: cytarabine
RxNorm normalized name: Cytarabine
DrugBank: Cytarabine (DB00987)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00002756
Drug: daunorubicin hydrochloride
RxNorm normalized name: Daunorubicin Hydrochloride
DrugBank: Daunorubicin (DB00694)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00002756
Drug: etoposide
RxNorm normalized name: Etoposide
DrugBank: Etoposide (DB00773)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00002756
Drug: prednisone
RxNorm normalized name: Prednisone
DrugBank: Prednisone (DB00635)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00002756
Drug: vincristine sulfate
RxNorm normalized name: Vincristine Sulfate
DrugBank: Vincristine (DB00541)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT03644056
Drug: IMC-001
RxNorm normalized name: IMC-18F1
DrugBank: Icrucumab (DB14824)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Different IMC-001 dose level for each cohort group (IMC-001 2 mg/kg etc. every 2 weeks)
Trial: NCT00674856
Drug: naproxcinod
RxNorm normalized name: Naproxcinod
DrugBank: Naproxcinod (DB06682)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 750mg
Trial: NCT00874328
Drug: Irinotecan
RxNorm normalized name: Irinotecan
DrugBank: Irinotecan (DB00762)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Irinotecan iv D1 q 3 weeks until maximum 6 cycles
Trial: NCT00874328
Drug: Cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: cisplatin 60mg/m2 iv D1 q 3weeks until maximum 6 cycles
Trial: NCT00874328
Drug: TS-1 (S-1)
RxNorm normalized name: Ts-1 (TN)
DrugBank: Gimeracil (DB09257)
FDA approved: no
EMA approved: yes
PMDA approved: no
Description: TS-1 po D1\~D14 q 3 weeks until maximum 6 cycles
Trial: NCT00005005
Drug: PTH
RxNorm normalized name: PTH
DrugBank: Parathyroid hormone (DB05829)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00005005
Drug: Alendronate
RxNorm normalized name: alendronate
DrugBank: Alendronic acid (DB00630)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT04907227
Drug: Docetaxel
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: IV infusion
Trial: NCT04907227
Drug: Prednisone
RxNorm normalized name: Prednisone
DrugBank: Prednisone (DB00635)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral tablets
Trial: NCT04907227
Drug: Dexamethasone
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Oral tablets